Lexington Medical and BOWA Medical Commercial Partnership Announced

Lexington Medical and BOWA Medical, a leading innovator of energy-based surgery products for medical applications, have entered into a commercial agreement the companies announced today.

Under the partnership, the companies will jointly market and sell the AEON™ and LOTUS™ portfolios in several global markets. The AEON Endostapler, made by Lexington Medical, brings advanced design engineering and patented technology to surgical stapling, while the LOTUS system, made by BOWA Medical, delivers the latest generation of powerful ultrasonic technology. Together the portfolios form a highly synergistic offering, providing surgeons and hospitals a new choice of innovative and high-quality surgical devices.

“We are excited to partner with BOWA Medical to offer our complimentary products to minimally-invasive surgeons and expand our reach in growing markets,” said Leon Amariglio, Founder and Chief Executive Officer, Lexington Medical. “BOWA Medical has a strong reputation in the electrosurgery and ultrasonic surgery market and we share the same high standards in engineering, manufacturing, and service to deliver a positive customer experience.”

Lexington Medical aims to disrupt the status quo in the stapling market with breakthrough design features including the advanced reload architecture, dual firing gear, and new precise articulation. The AEON Endostapler is being widely adopted as the stapler of choice by surgeons around the world for its proprietary features and exceptional staple formation. Developed over 30 years of experience, BOWA Medical is the only company that produces ultrasonic scalpels with torsional ultrasound. The patented and award-winning features make the LOTUS system especially efficient and reduces stray energy dissipation.

“We are impressed by the market shift occurring as a result of Lexington Medical’s successful efforts,” said Martin Heinrich, Chief Executive Officer, BOWA Medical. “Both companies share the same vision for product leadership and best-in-class manufacturing. We believe combining the quick, reliable dissection and vessel sealing from LOTUS with the strong, hemostatic staple lines from AEON will result in excellent outcomes for surgeons and their patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version